To extinguish the Ebola outbreak in the Democratic Republic of the Congo — where it has sickened at least 46 people, killed 26 and has spread to the provincial capital of Mbandaka — the World Health Organization says it's turning to an experimental vaccine.
The big picture: If it proves successful in halting this outbreak, the vaccine deployment could bring doctors and regulators closer to having an approved Ebola vaccine within the next few years.
The new FDA-approved drug from Amgen and Novartis that treats migraines, Aimovig, is the perfect example of why being the first in line for any new drug approval is so important.
Why it matters: Getting out of the gate first and pricing below independent cost-effectiveness estimates may give the pharmaceutical giants the upper hand even once the other migraine drugs hit the market.
Republicans on Capitol Hill have done little to publicly support the Trump administration's plan for drug prices — which some strategists see as a mistake, given the public fury over the issue.
Why it matters: There's still plenty of time for Hill Republicans to talk up the White House plan. But if they don't, it could be a missed opportunity to make it clear to voters ahead of midterms that they're serious about tackling prescription drug prices – especially given that the plan is relatively industry-friendly.
